Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03499899
Title A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals

triple-receptor negative breast cancer


Carboplatin + LAG525

Carboplatin + LAG525 + Spartalizumab

LAG525 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.